Marijuana Dependence Clinical Trial
Official title:
Vilazodone Treatment for Marijuana Dependence
Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
Status | Active, not recruiting |
Enrollment | 76 |
Est. completion date | March 2016 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Must meet DSM-IV criteria for marijuana dependence - Must be between the ages of 18 and 65 years old - If female and of childbearing potential, must agree to use acceptable method of birth control for duration of the trial. - Cannabis-positive urine drug screen at screening - Must consent to random assignment - Must be able to read and provide informed consent Exclusion Criteria: - Women who are pregnant, nursing, or plan to become pregnant during course of study - Must not have a history of or current psychotic disorder, bipolar disorder, or eating disorder - Must not pose a current suicidal or homicidal risk - Must not have evidence or history of serious medical disease - Must not require concomitant therapy with psychotropic medication or CYP3A4 inhibitors - Must not be currently dependent on other substances, with the exception of nicotine; - Patients who, in the investigator's opinion, would be unable to comply with study procedures or assessments |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Marijuana-negative Urine Drug Screens (UDS) | Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group. | 8 weeks | No |
Secondary | Weekly Cannabis Use Sessions | Self-report of weekly cannabis use sessions was measured using the Time Line Followback, a calendar-based instrument designed to assess substance consumption. | 8 weeks | No |
Secondary | Marijuana Craving and Withdrawal | The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) - 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly to all participants. Reported here is the mean MCQ purposefulness subscale score across 8 weeks. | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00875836 -
Buspirone Treatment for Marijuana Dependence
|
Phase 4 | |
Completed |
NCT00893269 -
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
|
Phase 1 | |
Completed |
NCT00490269 -
Ph1 Marinol Interaction Study - Part 2 - 1
|
Phase 1 | |
Completed |
NCT02579421 -
Hormones and Reduction in Co-users of Marijuana and Nicotine
|
N/A | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT00373295 -
Effect of Baclofen on Marijuana Withdrawal and Relapse
|
Phase 2 | |
Active, not recruiting |
NCT01827332 -
Effect of Oxytocin on Craving and Therapy Response
|
N/A | |
Completed |
NCT01335789 -
Effect of Oxytocin on Stress in Marijuana Users
|
N/A | |
Terminated |
NCT00438139 -
Ph1 Marinol Interaction Study - Part 1 - 1
|
Phase 1 | |
Completed |
NCT02955329 -
Vaping THC From Electronic Cigarettes
|
Phase 3 | |
Completed |
NCT02439814 -
Pregnenolone and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT01347762 -
Nabilone for Cannabis Dependence: A Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT01039415 -
Attempts to Stop/Reduce Marijuana Among Dependent Users
|
N/A | |
Completed |
NCT00270803 -
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana
|
N/A | |
Completed |
NCT01020019 -
Combined Pharmacotherapy for Cannabis Dependency
|
Phase 2/Phase 3 | |
Completed |
NCT02030665 -
Marijuana Treatment Project 4
|
N/A | |
Completed |
NCT00107588 -
Marijuana Treatment Project - 3
|
N/A | |
Completed |
NCT02011516 -
Baclofen Effects on Marijuana Dependence
|
Phase 2 | |
Recruiting |
NCT00598052 -
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
|
N/A | |
Completed |
NCT00350649 -
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
|
Phase 2 |